Atossa Therapeutics, Inc. (ATOS)
NCM · Healthcare · Biotechnology
$2.46
-5.02%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$21.2M
Shares Outstanding
8.6M
Exchange
NCM
Currency
USD
About Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -9.0M | -9.3M | -11.4M | -9.9M |
| Net Income | -8.4M | -8.7M | -10.9M | -9.6M |
| Diluted EPS | $-1.05 | $-1.05 | $nan | $-1.11 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -27.7M | -31.4M | -27.6M | -37.1M |
| Net Income | -27.0M | -30.1M | -25.5M | -34.8M |
| Diluted EPS | $-3.15 | $-3.60 | $-3.04 | $-4.04 |